A new targeted treatment for anaplastic large cell lymphoma
Stopping protein activity to stop anaplastic large cell lymphomas from growing.
Using existing drugs in a new way to treat high-risk acute lymphoblastic leukaemia
Finding drugs which target genes that drive high-risk acute lymphoblastic leukaemia.
Using synthetic antibodies to treat diffuse midline gliomas
Creating antibodies in the lab to treat diffuse midline gliomas and testing their effectiveness.
Targeting proteins to fight acute myeloid leukaemia
Understanding how proteins act inside acute myeloid leukaemia cells, to find new drug targets.
Using genetics to understand why acute myeloid leukaemia cells don’t respond to treatment
Looking at the genetics of bone marrow samples to see which genes affect resistance to treatment.
Paediatric Hepatic International Tumour Trial
Developing more effective treatments for patients who have a low chance of survival, while reducing treatment and side effects for other patients.
Developing less toxic therapies for children with acute lymphoblastic leukaemia
Our proposal will deliver novel, less toxic targeted therapies with the potential to advance current treatment regimens for B-ALL. This will improve current outcomes, reduce side-effects in B-ALL patients and ultimately lead to a better quality of life for patients and their families.
Developing innovative models to support research for kinder treatments for B cell lymphoma
Glo-BNHL trial is an international trial that will recruit children across the globe with relapse BNHL and assign them to the trial to receive a novel therapy. We are requesting funds to conduct biological studies alongside the trial to improve our understanding of this cancer.
Designing better treatments for paediatric ependymoma
Immunotherapy could be a potential treatment for ependymoma. To make immunotherapy effective we need to know more about how ependymoma works.